Buy Raloxifene (Evista) online

How and where to order Evista (Raloxifene HCl) 60 mg tablets online:

Shop:PHARMA SHOP - 10% discount coupon hf-5478
Sellers:RALOXIFENE STORES
Prices:from $1.01 per pill
Forms:Raloxifene Hydrochloride 60 mg tablets
Quantity:30-360 pills
Type:Raloxifene brand, Ralista brand, Evista brand and generics
Payment:Visa, Mastercard, AmEx, Bitcoin
Delivery:Regular and express mail service
Shipping:Worldwide, including USA, UK, Europe, Canada, Australia


Indications and usage:

Evista (Raloxifene Hydrochloride) is an estrogen agonist/antagonist indicated for:

  • Treatment and prevention of osteoporosis in postmenopausal women.
  • Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis.
  • Reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.

    Raloxifene is also in research studies for COVID-19, SARS-CoV-2, metastatic breast cancer, prostate cancer, pubertal gynecomastia in adolescent boys, schizophrenia, antidepressant effects.

    Important limitations: Evista is not indicated for the treatment of invasive breast cancer, reduction of the risk of recurrence of breast cancer, or reduction of risk of noninvasive breast cancer.


    Dosage and administration:

    The recommended dosage is one 60 mg Evista (Raloxifene Hydrochloride) tablet daily, which may be administered any time of day without regard to meals.

    For the indications in risk of invasive breast cancer the optimum duration of treatment is not known.


    Overdosage:

    In an 8-week study of 63 postmenopausal women, a dose of raloxifene hydrochloride 600 mg/day was safely tolerated. In clinical trials, no raloxifene overdose has been reported.

    In postmarketing spontaneous reports, raloxifene overdose has been reported very rarely (less than 1 out of 10,000 [ < 0.01% ] patients treated). The highest overdose has been approximately 1.5 grams. No fatalities associated with raloxifene overdose have been reported. Adverse reactions were reported in approximately half of the adults who took ?180 mg raloxifene HCl and included leg cramps and dizziness.

    Two 18-month-old children each ingested raloxifene HCl 180 mg. In these two children, symptoms reported included ataxia, dizziness, vomiting, rash, diarrhea, tremor, and flushing, as well as elevation in alkaline phosphatase.

    There is no specific antidote for Evista tablets.

    No mortality was seen after a single oral dose in rats or mice at 5000 mg/kg (810 times the human dose for rats and 405 times the human dose for mice based on surface area, mg/m2) or in monkeys at 1000 mg/kg (80 times the AUC in humans).


    Dosage forms and strengths:

    Evista (Raloxifene Hydrochloride) 60 mg tablets are white, elliptical, film coated (not scored) and imprinted with either 4165 or LILLY 4165 on one side in edible blue ink.


    Contraindications:

  • Active or past history of venous thromboembolism, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis.
  • Pregnancy.


    Warnings and precautions:

  • Venous thromboembolism: increased risk of deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis. Discontinue use 72 hours prior to and during prolonged immobilization.
  • Death due to stroke: increased risk of death due to stroke occurred in a trial in postmenopausal women with documented coronary heart disease or at increased risk for major coronary events. No increased risk of stroke was seen in this trial. Consider risk-benefit balance in women at risk for stroke.
  • Cardiovascular disease: Evista (Raloxifene HCl) tablets should not be used for the primary or secondary prevention of cardiovascular disease.
  • Premenopausal women: use is not recommended.
  • Hepatic impairment: use with caution.
  • Concomitant use with systemic estrogens: not recommended.
  • Hypertriglyceridemia: if previous treatment with estrogen resulted in hypertriglyceridemia, monitor serum triglycerides.


    Adverse reactions, side effects:

    Adverse reactions ( > 2% and more common than with placebo) include: hot flashes, leg cramps, peripheral edema, flu syndrome, arthralgia, sweating.

    To report suspected side effects of Evista (Raloxifene Hydrochloride) tablets contact Eli Lilly pharmaceutical company or your local FDA.


    Drug interactions:

  • Holestyramine: use with Evista is not recommended. Reduces the absorption and enterohepatic cycling of raloxifene.
  • Warfarin: monitor prothrombin time when starting or stopping this medicine.
  • Highly protein-bound drugs: use with Evista pills with caution. Highly protein-bound drugs include diazepam, diazoxide, and lidocaine. Raloxifene is more than 95% bound to plasma proteins.

    Related medications:

  • Cabergoline (Dostinex)
  • Testosterone Cypionate injections


    Use in specific populations:

    Pregnancy

    Evista is contraindicated for use in pregnant women, and is not indicated for use in females of reproductive potential. Based on mechanism of action, raloxifene may block the important functions that estrogen has during all stages of pregnancy.

    Lactation

    Evista is not indicated for use in females of reproductive potential. There is no information on the presence of raloxifene in human milk, the effects on the breastfed child, or the effects on milk production. However, based on mechanism of action, this drug may block the important functions that estrogen has in mammary tissue during lactation.

    Pediatric use

    Safety and effectiveness of Raloxifene Hydrochloride (Evista) 60 mg tablets tablets in pediatric patients have not been established.

    Geriatric use

    No overall differences in safety or effectiveness were observed between elderly people and younger subjects, and other reported clinical experience has not identified differences in responses between the old and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Based on clinical trials, there is no need for dose adjustment for geriatric patients.

    Renal impairment

    Evista (Raloxifene Hydrochloride) pills should be used with caution in patients with moderate or severe renal impairment.

    Hepatic impairment

    This medication should be used with caution in patients with hepatic impairment.


    Patient counseling information:

    Osteoporosis recommendations, including calcium and vitamin D supplementation

    For osteoporosis treatment or prevention, patients should be instructed to take supplemental calcium and/or vitamin D if intake is inadequate. Patients at increased risk for vitamin D insufficiency (e.g., over the age of 70 years, nursing home bound, chronically ill, or with gastrointestinal malabsorption syndromes) should be instructed to take additional vitamin D if needed. Weight-bearing exercises should be considered along with the modification of certain behavioral factors, such as cigarette smoking and/or excessive alcohol consumption, if these factors exist.

    Patient immobilization

    Evista should be discontinued at least 72 hours prior to and during prolonged immobilization (e.g., post-surgical recovery, prolonged bed rest), and patients should be advised to avoid prolonged restrictions of movement during travel because of the increased risk of venous thromboembolic events.

    Hot flashes or flushes

    Raloxifene HCl may increase the incidence of hot flashes and is not effective in reducing hot flashes or flushes associated with estrogen deficiency. In some asymptomatic patients, hot flashes may occur upon beginning Evista therapy.

    Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk of invasive breast cancer

    Use of this medicine is associated with the reduction of the risk of invasive breast cancer in postmenopausal women. Evista has not been shown to reduce the risk of noninvasive breast cancer. When considering treatment, physicians need to discuss the potential benefits and risks of raloxifene treatment with the patient.

    Evista (Raloxifene Hydrochloride) tablets are not indicated for the treatment of invasive breast cancer or reduction of the risk of recurrence.

    Patients should have breast exams and mammograms before starting this drug and should continue regular breast exams and mammograms in keeping with good medical practice after beginning treatment with Evista.


    Where to buy raloxifene online:

    To purchase Evista (Raloxifene) 60 mg tablets from reliable online pharmacies and drugstores at low prices please use resources described above on this webpage.


    Here is a list of popular medications containing raloxifene as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:

    Trade name of the drug Pharmaceutical forms and doses Companies
    Evista Tablets, Film-Coated; Oral; Raloxifene Hydrochloride 60 mg
  • Eli Lilly
  • Daiichi Sankyo
    		•
    Optruma Tablets, Film-Coated; Oral; Raloxifene Hydrochloride 60 mg
  • Eli Lilly
  • Leiras
  • Menarini
  • Merckle
  • Pensa Pharma
  • Pierre Fabre
  • Vitoria Laboratorios
    		•
    Ralista Tablets, Film-Coated; Oral; Raloxifene Hydrochloride 60 mg
  • Cipla
    		•

    •